Huan Zhang – InmunoES

Efficacy and safety of zanubrutinib and camrelizumab combined with CD19 chimeric antigen receptor T-cell in the treatment of relapsed/refractory diffuse large B-cell lymphoma

19 de March de 2026 by Huan Zhang

ObjectiveTo retrospectively analyze the efficacy and safety of zanubrutinib and camrelizumab combined with CD19 chimeric antigen receptor T-cell (CD19 CAR T-cell) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).MethodsThi…

Neoadjuvant immunotherapy for DNA mismatch repair proficient/microsatellite stable non-metastatic rectal cancer: a systematic review and meta-analysis

27 de January de 2025 by Huan Zhang

BackgroundNeoadjuvant immunotherapy (NIT) has been endorsed by clinical guidelines for the management of DNA mismatch repair deficiency/microsatellite instability-high (dMMR/MSI-H) locally advanced rectal cancer (LARC). Nonetheless, the therapeutic eff…